CANbridge Pharmaceuticals
Pharmaceutical Manufacturing • 
Burlington, Massachusetts, United States • 21-50 Employees
Company overview
| Headquarters | 4 Burlington Woods Dr, Burlington, Massachusetts 01803, US |
| Phone number | +1120361581 |
| Website | |
| NAICS | 3254 |
| Keywords | Biotechnology, Pharma, Life Sciences, Oncology, Rare Disease |
| Founded | 2012 |
| Employees | 21-50 |
| Socials |
Key Contacts at CANbridge Pharmaceuticals
Isabella Zhao
Director Of Investor Relations
Guokui Qin
Director, Antibody Discovery/Engineering And Gene Therapy, Department Of Global Research
Janny Wang
Qa Director
Jenny Tao
Director Of Quality Assurance
Albert Hsiao
Senior Commercial Director
Jason Jiang （江韌）
Strategic Finance Director
Tony Wei
Associate Director Of Supply Chain
Sophie Xie
Director Of Investor Relations
颖君 贾
Ra Director
丹 鞠
Associate Director
CANbridge Pharmaceuticals Email Formats
CANbridge Pharmaceuticals uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@canbridgepharma.com), used 72.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@canbridgepharma.com | 72.7% |
{first initial}{last name} | jdoe@canbridgepharma.com | 18.2% |
{first name}.{last name} | john.doe@canbridgepharma.com | 9.1% |
About CANbridge Pharmaceuticals
CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region. CANbridge has been recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, it has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib), in greater China, as well as rights to other novel candidates.
CANbridge Pharmaceuticals revenue & valuation
| Annual revenue | $6,901,460 |
| Revenue per employee | $141,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $22,100,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
CANbridge Pharmaceuticals has 21 employees across 10 departments.
Departments
Number of employees
Funding Data
CANbridge Pharmaceuticals has never raised funding before.
CANbridge Pharmaceuticals Tech Stack
Discover the technologies and tools that power CANbridge Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Tag managers
Security
Miscellaneous
SSL/TLS certificate authorities
JavaScript libraries
UI frameworks
Analytics
Sweden
Denmark
Germany
Israel
United KingdomFrequently asked questions
4.8
40,000 users
